

## Supplementary Table Legend

**Table S1: Summary of sequencing Metadata.** Related to Figure 1. Number of aligned reads, number of peaks, and sequencing protocol of each library, for  $Mbd3^{fl/-}$ ,  $Gatad2a^{-/-}$ , WT-1 and WT-2 engineered mouse reprogrammable systems.

**Table S2: Gene expression values of 8042 differential genes in four different drug inducible reprogramming systems.** Related to Figure 1. Calculated from PolyA+ RNA-seq, including protein-coding genes, pseudogenes, and lncRNAs, measured in the four different secondary reprogramming systems:  $Mbd3^{fl/-}$ ,  $Gatad2a^{-/-}$ , WT-1 and WT-2. Values are unit normalized FPKM (see **Methods**).

**Table S3: Gene expression values of 8705 differential genes in  $Mbd3^{fl/-}$  system.** Related to Figure 1. Gene expression values of 8705 differential genes in  $Mbd3^{fl/-}$  system, including polyA+ genes (protein-coding, pseudogenes, lncRNAs) and small RNA-seq (rRNA, miRNA, snoRNA). Values reported are FPKM.

**Table S4: Differential lncRNA expression and OSKM binding during conducive naïve iPSC reprogramming trajectory.** Related to Figure 1. Expanded lncRNA analysis beyond Ensembl annotation utilizing a PLAR-generated lncRNA dataset (see **Methods**). 560 differential lncRNA were identified during reprogramming, out of them 221 differential lncRNA not annotated in Ensembl. OSKM binding overlap, with associated Jaccard index, are included (same as presented in Fig. 1D).

**Table S5: Clusters of enhancers with different demethylation dynamics.** Related to Figure 3. Datasheet annotates clusters of enhancers with different demethylation dynamics as presented in **Fig. 3B**. Cluster 8 includes enhancers and super-enhancers with fast demethylation.

**Table S6: ESPG and CAPG differential groups.** Related to Figure 4. Detected differential gene groups during conducive iPSC reprogramming, including all differential genes and the differential genes subsets annotated as genes with epigenetically switched promoters (ESPGs) and genes with constitutively active promoters (CAPGs). Gene list is further divided to up-regulated and down-regulated list of each gene group.

# Supplementary Material

## Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules

**Asaf Zviran<sup>1,2\*</sup>, Nofar Mor<sup>1\*</sup>, Yoach Rais<sup>1\*</sup>, Hila Gingold<sup>1</sup>, Shani Peles<sup>1</sup>, Elad Chomsky<sup>1,3,4</sup>, Sergey Viukov<sup>1</sup>, Jason D. Buenrostro<sup>5,6</sup>, Roberta Scognamiglio<sup>7</sup>, Leehee Weinberger<sup>1</sup>, Yair S. Manor<sup>1</sup>, Vladislav Krupalnik<sup>1</sup>, Mirie Zerbib<sup>1</sup>, Hadas Hezroni<sup>3</sup>, Diego Adhemar Jaitin<sup>8</sup>, David Larastiaso<sup>8</sup>, Shlomit Gilad<sup>9</sup>, Sima Benjamin<sup>9</sup>, Ohad Gafni<sup>1</sup>, Awni Mousa<sup>1</sup>, Muneef Ayyash<sup>1</sup>, Daoud Sheban<sup>1</sup>, Jonathan Bayerl<sup>1</sup>, Alejandro Aguilera Castrejon<sup>1</sup>, Rada Massarwa<sup>1</sup>, Itay Maza<sup>1,10</sup>, Suhair Hanna<sup>1,11</sup>, Yonatan Stelzer<sup>13</sup>, Igor Ulitsky<sup>3</sup>, William J. Greenleaf<sup>13,14</sup>, Amos Tanay<sup>3,4</sup>, Andreas Trumpp<sup>7</sup>, Ido Amit<sup>7</sup>, Yitzhak Pilpel<sup>1</sup>, Noa Novershtern<sup>1#</sup> and Jacob H. Hanna<sup>1#%</sup>.**


\*These authors contributed equally. #Senior authors.

#Correspondence: Jacob H. Hanna ([jacob.hanna@weizmann.ac.il](mailto:jacob.hanna@weizmann.ac.il)), Noa Novershtern ([noa.novershtern@weizmann.ac.il](mailto:noa.novershtern@weizmann.ac.il)), Yoach Rais ([yoach.rais@weizmann.ac.il](mailto:yoach.rais@weizmann.ac.il))


%Lead Contact

Figure S1


**A**




**C**



**B**




**D**




**Fig. S1: Continuous changes in specific gene groups of interest during the course of deterministic naïve iPSC reprogramming.** Related to Fig. 1. **A.** Southern blot analysis for STEMCCA-OKSM integration in all lines used. Single copy integration was found in all lines used. Note that WT-2 and *Gatad2a*<sup>-/-</sup> have the same single copy integration pattern since these lines are isogenic and *Gatad2a*-KO by sgRNA was done at the final step after all transgenes and reporters were introduced. **B.** Transcription heatmap of Pluripotent genes, Primordial germ cell genes (PGCs), Mesenchymal to epithelial Transition (MET), and Epigenetic modifiers. Log<sub>10</sub>(FPKM) values are presented in *Mbd3*<sup>f/-</sup>, *Gatad2a*<sup>-/-</sup> and WT-1 systems. **C.** Transcription heatmap of differential lncRNAs, annotated according to mm10 (UCSC, December 2011). Log<sub>10</sub>(FPKM) values are presented. **D.** Transcription heatmap of differential microRNAs (FC>600), measured using small-seq assay in *Mbd3*<sup>f/-</sup> system.

Figure S2


**A** Epigenetic profile of differential enhancers




**B** ATAC profiles of differential enhancers in two optimally NuRD depleted systems






H3K27ac profiles of differential enhancers in two NuRD depleted systems and in WT




**C** Correlation between ATAC and H3K27ac signals on enhancers, in *Mbd3*<sup>-/-</sup> and *Gatad2a*<sup>-/-</sup> systems



**D** Correlation between H3K27ac signal on enhancers in *Mbd3*<sup>-/-</sup> and WT-1 systems






**G** Overlap between Enhancer clusters and ATAC-seq signals in *Mbd3*<sup>-/-</sup> vs. *C/EBPa*<sup>Tg</sup> systems



**Fig. S2: Massive epigenetic changes in enhancers detected during reprogramming.** Related to Fig. 2. **A.** Profiles of 40,174 differential enhancers along reprogramming, showing H3K4me1, H3K27ac, DNA methylation, ATAC accessibility and PolII binding. **B.** DNA accessibility (Top) and H3K27ac (bottoms) signals of 40,174 differential enhancers (rows), in *Mbd3<sup>f/-</sup>*, *Gatad2a<sup>-/-</sup>*, and WT-1 systems. **C.** Spearman correlation matrix comparing DNA accessibility (left) and H3K27ac (right) measured on enhancers in *Mbd3<sup>f/-</sup>* and *Gatad2a<sup>-/-</sup>* systems. **D.** Spearman correlation matrix comparing H3K27ac measured on enhancers in *Mbd3<sup>f/-</sup>* and WT systems. H3K27ac enhancer profile in WT-1 day8 is more similar to *Mbd3<sup>f/-</sup>* day4, than to day8. **E.** PCA of transcriptional profiles of two efficient reprogramming systems: *Mbd3<sup>f/-</sup>* MEFs and *C/EBPa<sup>Tg</sup>* B cells (Stadhouders et al., 2018) calculated over 8042 differential expressed genes (Fig. 1d). PCA emphasizes that both efficient systems converge to ESC/iPSC profile, despite the fact that starting cells are different, and the trajectory is different. **F.** Landscape around three pluripotency related genes (*Tfcp2l1*, *Mir290-295*, *Klf2*), showing ATAC-seq signal as measured in two different systems - *Mbd3<sup>f/-</sup>* MEFs and *C/EBPa<sup>Tg</sup>* B cells (Stadhouders et al., 2018), as well as for H3K27ac signal. Enhancers, highlighted by green box, are activated in both systems, but in different kinetics: around day1-day2 in *Mbd3<sup>f/-</sup>* MEF system, and around day4 in *C/EBPa<sup>Tg</sup>* B cell system. Signals are normalized to sample size (RPM), and data range is indicated on top left corner of the signal. **G.** Enrichment of enhancer clusters, as shown in Figure 3b, for DNA accessibility in *Mbd3<sup>f/-</sup>* MEF and *C/EBPa<sup>Tg</sup>* B cell systems, showing that cluster 8 significantly overlaps regions that are accessible during intermediate days in both systems. This correlation matrix shows that both systems converge to PSC profile in eight days, with a slightly faster kinetics of *Mbd3<sup>f/-</sup>* system in the first 2 days. Color shades represent FDR corrected enrichment p-value.

**Figure S3**









**Fig. S3: Global DNA demethylation changes during deterministic reprogramming.** Related to Fig. 3. **A.** Distribution of low (<0.02), mid (0.02-0.98) and high (>0.98) methylation in four genomic regions: Promoters (1000bp around the TSS), Enhancers, Gene body (TSS to TES) and Intergenic regions (1000bp tiles), calculated in each day of reprogramming. **B.** Flow cytometry measurements of both Nanog-GFP reactivation and SE-Mir290-tdTomato during reprogramming of secondary fibroblasts. Sorting for RGM-Mir290-tdTomato+/Nanog-GFP- cells and double negative cells was done at day 5. Please note that single positive Nanog-GFP+ cells do not exist in naive reprogramming conditions as applied herein. **C.** Reprogramming efficiency (measured by Oct4 GFP+ cells percentage) was measured after 8 reprogramming days of Gata2a-KO secondary MEF, following siRNA treatments targeting Tfp2l and Tfp2c, on days 0 and 3. Both treatments resulted in 20-30% reduction of reprogramming efficiency comparing to control specimen (siScramble). \*\* p<0.01, Student t-test (n=3).






**Fig. S4: Different epigenetic landscape shown in ESGP and CAPG promoters and enhancers.** Related to Fig. 4. **A.** ChIP-seq landscape showing binding of H3K27ac, H3K27me3, Oct4, c-Myc, alongside ATAC-seq and RNA-seq. Example of two genes with “epigenetically switched promoters” (ESPGs). Note that the change in H3K27ac and H3K27me3 corresponds to the change in expression (red box). Oct4 enhancer binding is highlighted in blue box **B.** Example of two genes with “consistently active promoters” (CAPGs). Note the constitutive high level of H3K27ac and low level of H3K27me3 regardless to the change in expression (red box). cMyc promoter binding is highlighted in purple box. Signals are normalized to sample size (RPM), and IGV data range is indicated on top left corner of the signal. **C.** DNA Methylation level of upregulated and downregulated ESGPs (red) and CAPGs (green), compared to all genes (gray), showing that CAPGs are hypomethylated, regardless of their expression pattern. **D.** Temporal profile of enhancer chromatin marks H3K27ac, H3K27me3, and gene expression of ESGPs and CAPGs that have an associated enhancer, along reprogramming. Each row corresponds to a single gene, genes are sorted according to their expression pattern and the same sorting was applied to the epigenetic marks in their corresponding enhancers.

# Figure S5



**Fig. S5: H3K9me2 and H3K27me3 show functionally distinct modes of epigenetic repression during conducive reprogramming.** Related to Fig. 5. **A.** Distribution of H3K9me2 signal in highly methylated (>0.98) and lowly methylated (<0.02) gene promoters, showing association of H3K9me2 with highly methylated promoters. \*  $p < 10^{-15}$  (Wilcoxon test) **B.** Functional enrichment of genes marked by the indicated epigenetic marks in their promoters. Four gene groups were analyzed: (i) Genes with H3K9me2 without DNA-methylation (n=4159), (ii) Genes with both H3K9me2 and DNA methylation in at least two-time points (n=248), (iii) Genes with H3K27me3 without H3K4me3 (n=2220) and (iv) Genes with both H3K27me3 and H3K4me3 in at least two-time points (n=2663). Annotations include GO categories, targets of TF binding<sup>46</sup>, or chromatin marks measured in ESC<sup>75</sup>. Gray shades indicate FDR corrected Fisher exact test p-values. Annotations with corrected p-value  $< 10^{-5}$  are presented. **C. Top:** Expression pattern of genes that gain bivalency during reprogramming (n=572). **Bottom:** Epigenetic modification level distribution of the same set of genes, showing a switch between H3K27ac and H3K27me3, and a constant state of accessibility. **D.** Chromatin accessibility of promoters marked by either repressive marks (H3K27me3, H3K9me2) or bivalent (H3K27me3+H3K4me3) modifications. Bivalent promoters are significantly more accessible than repressed promoters. \*\*  $p < 10^{-30}$  (Wilcoxon test). **E. Top:** Probability to observe the indicated epigenetic modification by its own in promoters (gray) and enhancers (black). **Bottom:** Probability to observe co-localized pairs of modifications in promoters and enhancers. **F.** Stacked bar chart of all combinations of the indicated chromatin modifications, as measured in promoters that gain bivalency (left) and in promoters that lose bivalency (right). Right – color code of frequent combinations (>3% of each sample).


**Figure S6**





**Fig. S6: Utilizing cross-correlation method for inferring time shifts between chromatin epigenetic changes and mRNA transcription.** Related to Fig. 5. **A. Top:** Cross correlation method<sup>50,51</sup> measures the overlap between two signals, while shifting the signals in their x-axis (convolution). In this case, the x-axis is time. The shift that gives the highest score is defined as the temporal offset between the signals. **Bottom:** example for cross-correlation method calculated in the promoter and enhancer of the gene Aim2. DNA accessibility and H3K27ac signal in promoter and enhancer are shown, alongside the shift of all signals from the transcription. **B. Left:** Distribution of cross-correlation temporal offset, measured between each of the indicated epigenetic modification and gene expression profile. The distribution was measured over 162 upregulated promoters that are covered by all indicated epigenetic modifications, thus comparing temporal offsets between epigenetic modifications on the same gene. Plus indicates mean, and square indicates median. \*  $p < 10^{-5}$  (paired-sample ttest). **Right:** Matrix showing the percentage of events in which the modification on the Y axis changes before the modification on the X axis. Calculated over the same set of 162 promoters as on the left panel. This matrix emphasizes that the order of events in the promoters is removal of H3K27me3, followed by deposition of H3K36me3, opening of chromatin and then deposition of other active marks (H3K27ac, PolII, H3K4me3). **C. Left:** Shuffling analysis was done as a negative control for cross-correlation analysis: cross correlation temporal offset was calculated between each ESPGs gene expression (n=3593) and the indicated epigenetic modification taken randomly from another gene. Showing loss of temporal order with random promoter shuffling. **Right:** Matrix as in (B), calculated over the shuffled promoters (n=3593), emphasizing the loss of order between the signals.

# Figure S7


**A** Time shifts between epigenetic signals and transcription in promoters and their associated enhancers



**B**




**C**



**D**

Correlation between transcription and PolII binding signal, measured in promoters and in associated enhancers.



**Fig. S7: Enhancer activation and PolII enhancer binding precede activation and binding of associated promoter.** Related to Fig. 5. **A.** Time shifts between the indicated chromatin modifications on promoter (gray) or associated enhancer (black) and gene expression, estimated with cross correlation method. The distribution was measured over all upregulated ESPGs (left) and downregulated ESPGs (right) which have a changing epigenetic modification (max-min z-score > 0.5) on both promoter and enhancer sites (numbers are indicated). Plus indicates mean, and square indicates median. \*  $p < 10^{-2}$ , \*\*  $p < 10^{-7}$  (Paired-sample t-test). **B. Left:** Expression pattern of PolII components Nelfa during conducive iPSC reprogramming. **Right:** enrichment of targets bound by Nelfa and Ser5p-PolII<sup>27</sup> among differential enhancers that are active in each day of reprogramming.  $-\log_{10}$  of Fisher exact test p-values is indicated. **C.** Two cases in which PolII binds the enhancers before it binds the associated promoter. The enhancers are marked by a green box, promoters are marked by a red box. **D.** Correlation distribution between PolII binding signal and gene expression, as measured in promoters and in enhancers of ESPGs that are bound by PolII (numbers are indicated). Correlations were calculated for each gene, over 11 time points.